Xwell, Inc. has determined that it incorrectly applied GAAP in relation to the impairment of its Treat business segment, resulting in an understatement of impairment expenses of $1,613,000 for Q3 2023. The company will be restating its financial statements for Q3 2023 and advises that previously issued reports and communications should no longer be relied upon.